SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-21-327268
Filing Date
2021-11-12
Accepted
2021-11-12 07:00:57
Documents
14
Period of Report
2021-11-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d249281d8k.htm   iXBRL 8-K 25222
2 EX-99.1 d249281dex991.htm EX-99.1 59989
6 GRAPHIC g249281g1112025854968.jpg GRAPHIC 2585
  Complete submission text file 0001193125-21-327268.txt   223899

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20211111.xsd EX-101.SCH 2898
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20211111_lab.xml EX-101.LAB 18123
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20211111_pre.xml EX-101.PRE 11409
7 EXTRACTED XBRL INSTANCE DOCUMENT d249281d8k_htm.xml XML 3350
Mailing Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110
Business Address 125 SUMMER STREET 16TH FLOOR BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

IRS No.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 211399450
SIC: 2834 Pharmaceutical Preparations